Abstract
An investigational tetravalent combined measles, mumps, rubella, and varicella vaccine and measles-mumps-rubella and varicella vaccines at separate injection sites given at the same visit were evaluated with respect to safety and cell-mediated and humoral immune responses at 6 weeks and 1 year after vaccination. Varicella seroconversion rates and lymphocyte proliferation responses were 100% for both vaccine groups at 6 weeks and 1 year. However, the antibody titer to varicella was lower in the combined vaccine group at 6 weeks, but there was no statistical difference in cell-mediated immune responses. One-year geometric mean titers were not statistically different. Seroconversion rates for measles, mumps, and rubella were 100% for both vaccine at 6 weeks and 1 year. Long-term follow-up of these immune responses is planned.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Viral / blood
-
Chickenpox Vaccine
-
Female
-
Herpesvirus 3, Human / immunology
-
Humans
-
In Vitro Techniques
-
Infant
-
Lymphocyte Activation
-
Male
-
Measles Vaccine / administration & dosage*
-
Measles Vaccine / adverse effects
-
Measles Vaccine / immunology
-
Measles virus / immunology
-
Measles-Mumps-Rubella Vaccine
-
Mumps Vaccine / administration & dosage*
-
Mumps Vaccine / adverse effects
-
Mumps Vaccine / immunology
-
Mumps virus / immunology
-
Rubella Vaccine / administration & dosage*
-
Rubella Vaccine / adverse effects
-
Rubella Vaccine / immunology
-
Rubella virus / immunology
-
Safety
-
Vaccines, Combined / administration & dosage*
-
Vaccines, Combined / adverse effects
-
Vaccines, Combined / immunology
-
Viral Vaccines / administration & dosage*
-
Viral Vaccines / adverse effects
-
Viral Vaccines / immunology
Substances
-
Antibodies, Viral
-
Chickenpox Vaccine
-
Measles Vaccine
-
Measles-Mumps-Rubella Vaccine
-
Mumps Vaccine
-
Rubella Vaccine
-
Vaccines, Combined
-
Viral Vaccines